In a recent Reuters article, IPOX® CEO Dr. Josef Schuster highlighted the strategic timing behind Ingram Micro's return to the U.S. stock market, as the global technology distributor seeks a valuation of up to $5.42 billion. Schuster emphasized that private equity firms, like Ingram's backer Platinum Equity, are capitalizing on favorable market conditions, strong demand, and the opportunity to monetize their investments.

Honeywell plans to spin off its advanced materials division, generating $3.7-$3.9 billion in revenue, into a new public company by 2026. Cerebras Systems is likely to delay its IPO due to a CFIUS review over foreign investment. Tokyo Metro's $2.35 billion IPO is multiple times oversubscribed internationally and will begin trading on October 23, 2024. TenneT explores a spin-off or stake sale of its $21.95 billion German unit.

In a recent Reuters article, IPOX® Research Analyst Dr. Lukas Muehlbauer discussed the strong debut of Upstream Bio (UPB.O) in the IPO market. The Waltham, Massachusetts-based drug developer saw its stock rise 26.5% above the IPO price, giving it a market value of $1.05 billion.

Several high-profile IPOs are set to debut across global markets. AI chipmaker Cerebras Systems plans a major Nasdaq listing, while Brazilian fintech PicPay and digital lender K Bank target significant offerings in 2025. In Europe, payments firm Ebury and sports supplements company Applied Nutrition prepare for London IPOs. Chinese AI firm Horizon Robotics seeks to raise $500 million in Hong Kong, and food delivery giant Talabat is eyeing a blockbuster Dubai listing with a potential valuation up to $15.1 billion.

Major upcoming IPOs include Titan America's expected $500 million raise in early 2025, potentially valuing it over $2 billion, and Spring Nature's anticipated IPO, possibly valuing the company at $10 billion by late 2024. In Asia, Midea Group raised $3.98 billion in Hong Kong's largest IPO in four years, while Enflame Technology aims to raise $280 million, targeting Shanghai's STAR board in late 2024.

Major upcoming IPOs include Titan America's expected $500 million raise in early 2025, potentially valuing it over $2 billion, and Spring Nature's anticipated IPO, possibly valuing the company at $10 billion by late 2024. In Asia, Midea Group raised $3.98 billion in Hong Kong's largest IPO in four years, while Enflame Technology aims to raise $280 million, targeting Shanghai's STAR board in late 2024.

In a recent Reuters article, IPOX® research analyst Lukas Muehlbauer highlighted strong institutional and retail demand for Bicara Therapeutics' IPO, which raised $315 million after upsizing twice. Bicara’s shares surged 46% in its debut, driven by confidence in its lead anti-cancer drug and notable backing from TPG and Biocon.

Several major IPOs are expected, including Titan America’s $500 million U.S. listing, Samsonite’s dual U.S.-Hong Kong offering, and Midea Group’s $3 billion Hong Kong IPO, the largest in the region since 2021. Carlyle’s Acrotec Group could raise $4.7 billion in Zurich. Other notable deals include Delivery Hero’s Talabat listing in Dubai and Advanta Enterprises planning a $500 million IPO in India by 2025.

In Bloomberg, IPOX® CEO Josef Schuster discussed the resurgence of SPACs, noting $2 billion raised in August. He emphasized SPACs as a viable alternative to traditional IPOs for niche sectors, with renewed interest from sponsors. IPOX® tracks these trends as companies explore new public listing avenues.